Panacea develops functional food products that incorporate targeted nutritional ingredients directly into everyday foods, eliminating the need for capsules, powders, or pills. This approach is designed to boost nutrient assimilation and consumer adherence, positioning the company within a functional food market projected to reach $280 billion by 2030. To scale production, Panacea plans to construct an Industry 4.0 manufacturing facility in Penne-d’Agenais (Lot-et-Garonne), enabling it to meet domestic demand and enter international markets. Funds will also fuel additional R&D to expand its portfolio of food-embedded active ingredients. Although the article does not disclose current revenue or user figures, the move to build a dedicated plant signals progress toward commercial-scale operations. The company’s strategy combines advanced manufacturing with nutrition science to offer a compelling alternative to conventional supplements.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2026